SGX Catalist-listed Livingstone Health Holding has announced that it will collaborate with Australian Securities Exchange-listed Osteopore to further develop the utilisation of 3D-printed micro-structures for bone and tissue healing and regeneration.

The two parties signed a Memorandum of Understanding (MoU) to combine the expertise of Livingstone Health’s orthopaedic surgeons and Osteopore’s innovations in natural tissue regeneration.

Based in Australia and Singapore, Osteopore’s innovations include bioresorbable implants made from patented scaffolds that are 3D-printed. These scaffolds dissolve naturally over time, leaving only natural, healthy bone tissue.

This innovation improves surgical outcomes and lowers medical costs, as it significantly reduces post-surgery complications compared to traditional procedures such as bone grafting and permanent implants.

Within the Livingstone Health's orthopaedic team, two specialists – Dr. Edwin Tan and Dr. James Tan – intend to apply two of Osteopore’s products in in two upcoming surgeries, marking the first orthopaedic application of Osteopore implants in Singapore. The first is Osteomesh, a rigid yet flexible bioresorbable scaffold, which will be used for tendon repair, including rotator cuff and Achilles tendon. The second is Osteopore’s latest product, a synthetiuc fibular strut graft which will be used for bone reconstruction in the upper and lower limbs.